2023 World Conference on Lung Cancer (Posters)-EP13.04. Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer

EP13.04. Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the effectiveness of prophylactic cranial irradiation (PCI) in limited-stage small cell lung cancer (LS-SCLC). The researchers retrospectively analyzed 271 LS-SCLC patients who underwent definitive chemoradiation. The patients were categorized into two groups: those with early brain metastasis occurring before extracranial recurrence (ECR) and those with late brain metastasis occurring after ECR. The clinical endpoints analyzed were intracranial recurrence (ICR), ECR, progression-free rate (PFR), and overall survival (OS).<br /><br />The results showed that the application of PCI was associated with higher PFR and OS. However, there was no statistically significant difference in ICR or ECR based on the application of PCI. Multivariate analysis did not show any association between PCI and the clinical endpoints. The competing risk of the first recurrence with ICR was significantly decreased with the application of PCI.<br /><br />The researchers identified stage III disease, sequential treatment, and stable disease after thoracic radiation as ECR risk factors. For patients without these risk factors, the application of PCI was associated with increased OS and a decreased risk of early brain metastasis.<br /><br />In conclusion, the study suggests that PCI may be effective in preventing early brain metastasis rather than late brain metastasis after ECR. It is indicated that only patients with a low risk of ECR may currently benefit from PCI.

Asset Subtitle

Tae Hoon Lee

Meta Tag

Speaker Tae Hoon Lee

Topic SCLC & Neuroendocrine Tumors: LS-SCLC

Keywords

prophylactic cranial irradiation

limited-stage small cell lung cancer

LS-SCLC

chemoradiation

brain metastasis

intracranial recurrence

extracranial recurrence

progression-free rate

overall survival

stage III disease